Who is sponsoring NCT04753372?

NCT04753372 is sponsored by Maatschap Cardiologie Zwolle.

What drugs are being tested in NCT04753372?

Interventions in NCT04753372: Rivaroxaban 2.5 MG [Xarelto].

What condition does NCT04753372 study?

NCT04753372 studies Coronary Artery Disease (CAD), Peripheral Arterial Disease (PAD).

Is NCT04753372 still recruiting?

NCT04753372 is currently completed. Last updated 28 September 2023.

Last reviewed 2023-09-28 · How we verify

NCT04753372

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Rivaroxaban Plus Aspirin in Patients With Chronic Coronary Syndrome and High Ischemic Risk

Completed Last updated 28 September 2023

What this trial tests

trial testing Rivaroxaban 2.5 MG [Xarelto] in Coronary Artery Disease (CAD) in 645 participants. Completed in 13 September 2023.

Timeline

21 December 2020

Primary endpoint
13 September 2023

13 September 2023

Quick facts

Lead sponsor	Maatschap Cardiologie Zwolle
Status	Completed
Study type	OBSERVATIONAL
Enrollment	645
Start date	21 December 2020
Primary completion	13 September 2023
Estimated completion	13 September 2023
Sites	12 locations across Netherlands

Drugs / interventions tested

Rivaroxaban 2.5 MG [Xarelto] — full drug profile →

Conditions studied

Coronary Artery Disease (CAD) — all drugs for Coronary Artery Disease (CAD) →
Peripheral Arterial Disease (PAD) — all drugs for Peripheral Arterial Disease (PAD) →

Sponsor

Maatschap Cardiologie Zwolle — full company profile →

Who can join

18 and older, any sex, with Coronary Artery Disease (CAD) or Peripheral Arterial Disease (PAD). Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Registry to describe the impact in terms of effectiveness and safety of the combination treatment of rivaroxaban 2.5 mg twice daily with aspirin on clinical outcomes and practices in a real-life Dutch patient population that are at high risk of ischemic events.

Publications & conference data

2 peer-reviewed publications reference this trial (live from Europe PMC):

Efficacy and Safety of Low-Dose Rivaroxaban in High-Ischemic-Risk Patients with Chronic Coronary Syndrome: Rationale and Design of the DUTCH CCS Registry.
Selvarajah A, van der Heijden DJ, Remkes WS, Ten Berg JM, et al · · 2025 · PMID 40648772 · DOI 10.3390/jcm14134401
Efficacy and Safety of Low Dose Rivaroxaban in High Ischemic Risk Patients with Chronic Coronary Syndrome: Rationale and Design of the Dutch CCS Registry
Selvarajah A, Heijden DJvd, Remkes WS, Berg JMt, et al · · 2024 · DOI 10.21203/rs.3.rs-3845930/v1

Verify or expand the search:

Other trials of Rivaroxaban 2.5 MG [Xarelto]

Trials testing the same drug.

NCT05077683 — Direct Oral Anticoagulants for Prevention of lEft ventRIcular Thrombus After Anterior Acute Myocardial InFarction - APER · Phase 3 · completed
NCT04838808 — Rivaroxaban in Type 2 Myocardial Infarctions · Phase 2, PHASE3 · completed

Other recruiting trials for Coronary Artery Disease (CAD)

Currently open trials in the same condition.

NCT07479433 — The NAVIGATE-PCI Registry: A New Approach to VIew CT-derived Guidance Ahead of Stenting To Plan Efficient PCI · recruiting
NCT07349875 — Colchicine Treatment for Non-Flow-Limiting Coronary Plaque by Coronary CTA: A Randomized Controlled Trial · Phase 4 · recruiting
NCT07277686 — AI Facial Analysis Algorithm to Screening Coronary Artery Disease in High-Risk Community Population · recruiting
NCT07148518 — Comparison of Upper and Lower Limb Maximal Exercise Capacities and Arterial Stiffness in Patients With CAD · recruiting
NCT07392021 — Effects of a Recovery-Promoting Program in Patients Undergoing CABG Surgery · NA · active not recruiting

Other Maatschap Cardiologie Zwolle trials

Trials by the same sponsor.

NCT04837404 — Ultrasound Guided Transfemoral Complex Large-bore PCI Trial · NA · completed
NCT03846752 — Complex Large-bore Radial Percutaneous Coronary Intervention (PCI) Trial · NA · completed
NCT03845010 — Elimination of VPB With Ablation Versus Anti-arrhythmic Drug Treatment · NA · completed
NCT03424941 — The TransCatheter Valve and Vessels Trial · NA · completed

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT04753372 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Maatschap Cardiologie Zwolle
Last refreshed: 28 September 2023

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04753372.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing